236 related articles for article (PubMed ID: 19043838)
1. Raltegravir phase III study data released.
AIDS Patient Care STDS; 2008 Nov; 22(11):917. PubMed ID: 19043838
[No Abstract] [Full Text] [Related]
2. Raltegravir as effective as efavirenz in 144-week data.
AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
[No Abstract] [Full Text] [Related]
3. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651
[No Abstract] [Full Text] [Related]
4. No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou H; Sayana S; Acosta E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
[No Abstract] [Full Text] [Related]
5. Trial will evaluate a once-daily dose of raltegravir.
AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
[No Abstract] [Full Text] [Related]
6. Elvucitabine data released at CROI.
AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
[No Abstract] [Full Text] [Related]
7. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
8. [HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
Delaugerre C
Pathol Biol (Paris); 2010 Dec; 58(6):403-5. PubMed ID: 19481371
[No Abstract] [Full Text] [Related]
9. Rilpivirine: a step forward in tailored HIV treatment.
Schrijvers R; Desimmie BA; Debyser Z
Lancet; 2011 Jul; 378(9787):201-3. PubMed ID: 21763920
[No Abstract] [Full Text] [Related]
10. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
11. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Arazo Garcés P; Omiste Sanvicente T
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
[TBL] [Abstract][Full Text] [Related]
12. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
Kravchenko AV
Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
[TBL] [Abstract][Full Text] [Related]
13. [Valuable combination partner. Great benefit for therapy naive patients].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
[No Abstract] [Full Text] [Related]
14. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
15. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
16. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
Vento S; Vallone A
AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
[No Abstract] [Full Text] [Related]
17. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
18. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
[No Abstract] [Full Text] [Related]
19. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
[No Abstract] [Full Text] [Related]
20. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
